ANI Pharmaceuticals, Inc. (ANIP) vs Generate Biomedicines, Inc. (GENB)

A side-by-side comparison of ANI Pharmaceuticals, Inc. and Generate Biomedicines, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
ANI Pharmaceuticals, Inc. logo
ANIP
ANI Pharmaceuticals, Inc.
$1.65B
$72.58HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Generate Biomedicines, Inc. logo
GENB
Generate Biomedicines, Inc.
$1.78B
$13.91HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ANIP vs GENB

growth of $100 · dividends reinvested · last 1y
ANIP -4.9% (-4.9%/yr)GENB +10.0% (+10.0%/yr)GENB compounded faster over this window
100120140160Start $100$95$110
ANIP GENB

ANIP vs GENB: by the numbers

  • •GENB is the larger company ($1.78B vs $1.65B market cap).
  • •ANIP is profitable (10.82% net margin) while GENB runs a net loss (-636.99%).

Metrics side by side

Valuation

MetricANIPGENB
P/E ratio15.68N/A
Forward P/E7.83N/A
P/S ratio1.69N/A
P/B ratio2.763.91
EV / EBITDA6.87N/A

Profitability

MetricANIPGENB
Gross margin51.01%100.00%
Operating margin15.35%-737.04%
Net margin10.82%-636.99%
ROE17.72%N/A
ROIC9.26%-94.79%

Growth (annualized)

MetricANIPGENB
Revenue CAGR (5Y)35.61%N/A
Total return CAGR (5Y)16.86%N/A

Frequently asked

Is ANIP or GENB more profitable?
ANIP runs the higher net margin — ANIP at 10.82% versus GENB at -636.99%.

Go deeper

Full ANIP analysisFull GENB analysisInteractive comparison tool

Dig into the metrics

ANI Pharmaceuticals P/E ratioANI Pharmaceuticals ROEGenerate Biomedicines ROEANI Pharmaceuticals operating marginGenerate Biomedicines operating marginANI Pharmaceuticals revenue growthGenerate Biomedicines revenue growthANI Pharmaceuticals free cash flowGenerate Biomedicines free cash flow

ANI Pharmaceuticals & Generate Biomedicines appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.